ArticleArchiv der Pharmazie2026
Assessment of the Targeted Therapeutic Potential of Naringenin-Benzyl Piperazine Derivatives on Hypoxia-Induced JAK/STAT Pathway in Breast and Ovarian Cancers.
Article in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Naringenin, a prominent member of the flavanone family of polyphenols, is widely distributed in cherries, tomatoes, and citrus fruits, such as grapefruits, as well as in medicinal plants. In vitro and in vivo investigations have shown that naringenin, naringenin-loaded nanoparticles, and its derivatives, whether administered singularly or in conjunction with other anticancer agents, can effectively counteract carcinogenic agents and inhibit the advancement of various malignancies, including colon cancer, lung neoplasms, ovarian cancer, and breast cancer. In this study, the effects of naringenin-benzylpiperazines (3b, 3f, and 3g) were investigated on breast ductal carcinoma MCF7 (ER-α+), human breast adenocarcinoma SK-Br, human triple-negative breast metastatic adenocarcinoma MDA-MB-231, ovarian cancer NIH-OVCAR-3, and human ovarian cancer SKOV-3 cells. The IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.